EHA2026 Congress
Trials whose public commentary places their results at EHA2026 Congress, Jun 11–14, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
16 trials: 2 with reports and 14 with no report yet. Organised by European Hematology Association (EHA); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| AL amyloidosis · 1 | |||||||
| LINKER-AL2 linvoseltamab placed at EHA2026 Congress by 4 sources NCT06292780 · Regeneron Pharmaceuticals | relapsed or refractory systemic light chain amyloidosis | Phase 1/Phase 2 | 149 | 25 | Focused | Nov 1, 2026 | Preview |
| Diffuse large B-cell lymphoma · 1 | |||||||
| EPCORE DLBCL-1 epcoritamab placed at EHA2026 Congress by 3 sources NCT04628494 · Genmab | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | 113 | 19 | Focused | Oct 31, 2026 | Preview |
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Diffuse large B-cell lymphoma · 1 | |||||||
| STARGLO glofitamab placed at EHA2026 Congress by 5 sources NCT04408638 · Hoffmann-La Roche DeepView → | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | Deep | View | |||
| Multiple myeloma · 8 | |||||||
| MonumenTAL-3 talquetamab plus daratumumab plus pomalidomide; talquetamab plus daratumumab placed at EHA2026 Congress by 14 sources NCT05455320 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| MajesTEC-3 teclistamab plus daratumumab placed at EHA2026 Congress by 9 sources NCT05083169 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| MajesTEC-4 teclistamab placed at EHA2026 Congress by 6 sources NCT05243797 · European Myeloma Network B.V. DeepView → | newly diagnosed multiple myeloma following autologous transplantation | Phase 3 | Deep | View | |||
| MajesTEC-9 teclistamab placed at EHA2026 Congress by 3 sources NCT05572515 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| SUCCESSOR-2 mezigdomide placed at EHA2026 Congress by 3 sources NCT05552976 · Bristol-Myers Squibb DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| DREAMM-7 belantamab mafodotin placed at EHA2026 Congress by 2 sources NCT04246047 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| DREAMM-8 belantamab mafodotin placed at EHA2026 Congress by 2 sources NCT04484623 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| DREAMM-9 belantamab mafodotin plus bortezomib plus lenalidomide plus dexamethasone placed at EHA2026 Congress by 2 sources NCT04091126 · GlaxoSmithKline DeepView → | newly diagnosed multiple myeloma | Phase 1 | Deep | View | |||
| Other · 5 | |||||||
| frontMIND tafasitamab plus lenalidomide placed at EHA2026 Congress by 7 sources NCT04824092 · Incyte Corporation DeepView → | newly diagnosed high-intermediate and high-risk DLBCL | Phase 3 | Deep | View | |||
| DALY 2-EU zamtocabtagene autoleucel (MB-CART2019.1) placed at EHA2026 Congress by 3 sources NCT04844866 · Miltenyi Biomedicine GmbH StandardView → | Not given | Phase 2 | Standard | View | |||
| EPCORE FL-1 epcoritamab placed at EHA2026 Congress by 3 sources NCT05409066 · Genmab DeepView → | relapsed or refractory follicular lymphoma | Phase 3 | Deep | View | |||
| PALOMA Drug not named yet placed at EHA2026 Congress by 3 sources NCT04606381 · Janssen Research & Development, LLC DeepView → | advanced solid malignancies | Phase 1 | Deep | View | |||
| RevSTAR-123 Drug not named yet placed at EHA2026 Congress by 2 sources NCT05949125 · AvenCell Europe GmbH FocusedView → | Not given | Phase 1 | Focused | View | |||